StockData
Nasus Pharma Ltd logo

Nasus Pharma Ltd (NSRX) company profile

NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 25, 2026Score 6/30
$2.61−0.05 (-1.88%)

Close on Nov 17, 2026Market cap $23.53MP/E –Yield –

About Nasus Pharma

Pharmaceutical Preparations, SIC 2834

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company that develops powder-based intranasal medications for acute and emergency medical situations. The company utilizes proprietary technology to deliver uniform spherical powder formulations into the nasal cavity for rapid drug absorption. Its primary product candidate is NS002, an intranasal epinephrine powder spray designed to treat severe allergic reactions. It also develops NS001, an intranasal naloxone candidate for opioid overdose, alongside preclinical programs exploring intranasal treatments for seizures, organophosphate poisoning, and vomiting. Because its product candidates remain in clinical development without regulatory approval, the company currently has no commercial customers, targeting patients who require immediate emergency care.

The company is incorporated and headquartered in Tel Aviv, Israel. It operates as a development-stage enterprise without commercial manufacturing facilities, relying on external contractors for drug supply, clinical operations, and laboratory materials. Its research footprint includes clinical trial operations in Canada, where it evaluates its investigational therapies in adult patient cohorts.

Summary of the business section of Nasus Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Nasus Pharma Ltd
Headquarters
Tel Aviv - Yafo, L3
Address
29 Harakevet St 6618003
Phone
972 54-255-3956
Industry
Pharmaceutical Preparations
Incorporated in
L3
Fiscal year ends
December 31
Auditor
Brightman Almagor Zohar & Co, Tel-Aviv, Israel

Stock & identifiers

Ticker
NSRX
Exchange
NYSE
IPO date
Aug 14, 2025
Shares outstanding
9M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
2029039
CUSIP
M7071P109
FIGI
BBG01W00P7X8
Share class FIGI
BBG01W00P8Y5
EIN
51-6022712

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brendan P. O'GradyChief Executive Officer, Director–
Dan Benjamin TelemanChief Executive Officer, Director163,541
Dalia MegiddoChief Development Officer, Director1,894,068
Oren ElmaliahInterim CFO–
Eyal RubinChief Financial Officer–
Sharon ShachamDirector–
David SilbermanDirector–
Isaac IsraelDirector–
Ronnie HershmanDirector1,338,463

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 14, 2025
Offer price
$8.00
Exchange
NYSE American
First trading day
Aug 13, 2025
First-day close
$8.25+3.1%
Lock-up ends (est.)
Feb 9, 2026

“Per Share Total Initial public offering price $ 8.00 $ 10,000,000 Underwriting discounts and commissions (1) $ 0.56 $ 700,000 Proceeds to us (before expenses) $ 7.44 $ 9,300,000 (1) Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the initial public offering”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?